伏立康唑与康艾注射液联合应用于肺部真菌感染肺癌治疗的临床效果观察
|
摘要
目的观察伏立康唑与康艾注射液联合应用于肺部真菌感染肺癌治疗的临床效果。方法将2017年1月～2018年7月在该院接受治疗的110例肺癌合并肺部真菌感染患者随机分为实验组(n=55)和对照组(n=55)。对照组予伏立康唑片口服治疗,实验组在对照组的基础上加用康艾注射液静脉滴注治疗。对比两组患者治疗14 d后的临床疗效、机体功能状态及临床症状改善情况。结果实验组治疗总有效率高于对照组(47.27%vs 27.27%χ~2=2.486,P=0.013);KPS评分高于对照组[(82.41±9.31)分vs(73.40±8.22)分,(t=5.380,P<0.001)];体温和白细胞恢复时间、住院时间均少于对照组,对比差异有统计学意义(t体温恢复时间=16.013,P<0.001;t白细胞恢复时间=10.890,P<0.001;t住院时间=9.934,P<0.001)。结论伏立康唑与康艾注射液联合给药有利于提高肺癌合并肺部真菌感染患者的临床治疗效果,改善患者的机体功能状态,缩短治疗时间。
Objective To observe the clinical effect of voriconazole combined with Kangai injection in the treatment of lung fungal infection with lung cancer. Methods 110 patients with lung cancer complicated with pulmonary fungal infection who were treated in our hospital from January 2017 to July 2018 were randomly divided into two groups. The control group was treated with voriconazole tablets orally, and the experimental group was treated with Kangai injection intravenously on the basis of the control group. The clinical efficacy, functional status and clinical symptoms of the two groups were compared after 14 days of treatment. Results The clinical efficacy of the experimental group was better than that of the control group 47.27% vs 27.27%(Z=2.486, P=0.013), the KPS score of the experimental group was higher than those of the control group [(82.41±9.31)points vs(73.40±8.22)points,(t=5.380, P<0.001)], the body temperature,white blood cell recovery time and hospitalization time of the experimental group were lower than those of the control group, and the differences were statistically significant(t body temperature recovery time =16.013, P <0.001; t white blood cell recovery time =10.890, P <0.001; t hospitalization time =9.934, P <0.001). Conclusion The combination of voriconazole and Kangai injection is beneficial to improve the clinical treatment effect of patients with lung cancer complicated with pulmonary fungal infection, improve the functional status of patients and shorten the time of treatment.
Objective To observe the clinical effect of voriconazole combined with Kangai injection in the treatment of lung fungal infection with lung cancer. Methods 110 patients with lung cancer complicated with pulmonary fungal infection who were treated in our hospital from January 2017 to July 2018 were randomly divided into two groups. The control group was treated with voriconazole tablets orally, and the experimental group was treated with Kangai injection intravenously on the basis of the control group. The clinical efficacy, functional status and clinical symptoms of the two groups were compared after 14 days of treatment. Results The clinical efficacy of the experimental group was better than that of the control group 47.27% vs 27.27%(Z=2.486, P=0.013), the KPS score of the experimental group was higher than those of the control group [(82.41±9.31)points vs(73.40±8.22)points,(t=5.380, P<0.001)], the body temperature,white blood cell recovery time and hospitalization time of the experimental group were lower than those of the control group, and the differences were statistically significant(t body temperature recovery time =16.013, P <0.001; t white blood cell recovery time =10.890, P <0.001; t hospitalization time =9.934, P <0.001). Conclusion The combination of voriconazole and Kangai injection is beneficial to improve the clinical treatment effect of patients with lung cancer complicated with pulmonary fungal infection, improve the functional status of patients and shorten the time of treatment.
引文
[1]顾晓雯,崔磊,江建芹,等.CT灌注成像评估肺癌疗效的研究进展[J].中华放射学杂志, 2016,50(10):804-806.
[2]卢宏丽,卢宏霞.培美曲塞联合顺铂治疗晚期肺腺癌的疗效观察[J].中国药物与临床,2017,17(10):1500-1502.
[3]贾佳,张智慧.细胞学标本在非小细胞肺癌基因检测中的应用[J].中国肿瘤临床与康复,2017,24(3):370-372.
[4]张喜荣,黄孝静,陈艳华,等.伏立康唑联合康艾注射液治疗肺癌合并肺部真菌感染的临床效果[J].西部医学,2015,27(12):1870-1873.
[5]刘文,李莎,颜笑,等.用HPLC法测定人血浆中伏立康唑的浓度及其应用[J].药学服务与研究,2017,17(5):387-390.
[6]孙远南,陆明荣,倪慧,等.肺癌患者肺部真菌感染应用伏立康唑联合康艾注射液治疗的疗效观察[J].中华医院感染学杂志,2015,25(23):5377-5379.
[7]李爽,张剑宇.益气扶正中药注射剂协同化疗治疗Ⅲ期、Ⅳ期非小细胞肺癌系统评价[J].中医学报,2018,33(2):181-189.
[8]丛仔红,马宁,焦相学.硬膜外自控镇痛对肺癌术后肺部感染及应激指标的影响[J].实用临床医药杂志,2016,20(15):184-185.
[9]薛阳,李红磊,张薇,等.伏立康唑抗真菌作用研究进展[J].人民军医,2016,59(7):746-748.
[10]袁一凡,陈晓月,刘保霞,等.UPLC-MS/MS法同时测定康艾注射液中11种成分[J].中草药,2017,48(13):2660-2665.
[2]卢宏丽,卢宏霞.培美曲塞联合顺铂治疗晚期肺腺癌的疗效观察[J].中国药物与临床,2017,17(10):1500-1502.
[3]贾佳,张智慧.细胞学标本在非小细胞肺癌基因检测中的应用[J].中国肿瘤临床与康复,2017,24(3):370-372.
[4]张喜荣,黄孝静,陈艳华,等.伏立康唑联合康艾注射液治疗肺癌合并肺部真菌感染的临床效果[J].西部医学,2015,27(12):1870-1873.
[5]刘文,李莎,颜笑,等.用HPLC法测定人血浆中伏立康唑的浓度及其应用[J].药学服务与研究,2017,17(5):387-390.
[6]孙远南,陆明荣,倪慧,等.肺癌患者肺部真菌感染应用伏立康唑联合康艾注射液治疗的疗效观察[J].中华医院感染学杂志,2015,25(23):5377-5379.
[7]李爽,张剑宇.益气扶正中药注射剂协同化疗治疗Ⅲ期、Ⅳ期非小细胞肺癌系统评价[J].中医学报,2018,33(2):181-189.
[8]丛仔红,马宁,焦相学.硬膜外自控镇痛对肺癌术后肺部感染及应激指标的影响[J].实用临床医药杂志,2016,20(15):184-185.
[9]薛阳,李红磊,张薇,等.伏立康唑抗真菌作用研究进展[J].人民军医,2016,59(7):746-748.
[10]袁一凡,陈晓月,刘保霞,等.UPLC-MS/MS法同时测定康艾注射液中11种成分[J].中草药,2017,48(13):2660-2665.